Prostate Cancer UK Professionals

Scientific Paper Published in Cancer Medicine, titled: Detection of Genome-Wide IGF-1R Recruitment to Enhancer and Promoter Regions of Chromatin in Clinical Prostate Cancers. Written by Mills et al.

Could IGF-1R recruitment to chromatin regulatory regions be important in #ProstateCancer?

A brilliant team based @ndsurgicalsci.bsky.social share exciting new findings in Cancer Medicine.

Grab a ☕ and read: doi.org/10.1002/cam4...

Woman sitting on sofa watching a webinar on her phone.

🎦 Watch Dr Bunmi Olajide in collaboration with @nasgp.bsky.social for practical guidance on prostate cancer detection, PSA testing & tackling health inequalities.

➡️ View here bit.ly/46a5WyZ

💙 1 in 8 UK men will develop prostate cancer — but the risk is twice as high for men of African ancestry.

Yet, research in this group is still limited. That needs to change.

#MensHealth #ProstateCancer

Scientific Review Paper Published in BJUI Compass, titled: Emerging tools for the early detection of prostate cancer. Written by Haider et al.

Could imaging, genetic and biomarker tests improve early #ProstateCancer detection?

A team led by Prof Prabhakar Rajan @qmbci.bsky.social explore different detection strategies in their latest publication in @bjuijournal.bsky.social.

Grab a ☕ and read: doi.org/10.1002/bco2...

An individual is sitting at a kitchen counter watching a webinar on a tablet and holding a yellow mug. The kitchen has wooden shelves stocked with various kitchenware.

🎦 On-demand webinar: Dr Bunmi Olajide with @NASGP on early detection of prostate cancer — risk assessment, PSA testing & health inequalities.

➡️Watch here: bit.ly/46a5WyZ

Don't miss this: Claire Fletcher, part of the Hormone Dependent Cancer founding group, shares why this upcoming event is a must-attend for anyone working in the field. PLUS: abstract deadline extension to 1/10 bit.ly/4fqWdqL

Scientific Paper Published in The EMBO Journal, titled: Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells. Written by Lai et al.

Can specific gene mutations drive CDK7 inhibitor resistance in #ProstateCancer?

A brilliant team led by @simak.bsky.social @imperialcollegeldn.bsky.social share exciting new findings in @embojournal.org.

Grab a ☕ and read: doi.org/10.1038/s443...

It's an excellent scheme for establishing connections in your research areas, and it creates opportunities for potential future collaborations. James Thetford, Mentee. University of Surrey.

I am enthusiastic about providing help to ensure researchers succeed and thrive. Professor Jason Carroll, Mentor. University of Cambridge.

🤝Our mentoring scheme brings #ProstateCancer researchers from different institutions together.

🚀To help navigate challenges & build successful careers - delivering maximum impact for men.

💪Together, we're building a stronger, more connected, research community.
prostatecanceruk.org/research/for...

It's an excellent scheme for establishing connections in your research areas, and it creates opportunities for potential future collaborations. James Thetford, Mentee. University of Surrey.

I am enthusiastic about providing help to ensure researchers succeed and thrive. Professor Jason Carroll, Mentor. University of Cambridge.

🤝Our mentoring scheme brings #ProstateCancer researchers from different institutions together.

🚀To help navigate challenges & build successful careers - delivering maximum impact for men.

💪Together, we're building a stronger, more connected, research community.
prostatecanceruk.org/research/for...

I'm looking forward to meeting like-minded researchers and hearing about all the exciting advances in prostate cancer research. Dr Sarah Gosling, Prostate Cancer UK Fellow.

Exciting🌟From Ideas to Innovation🌟Updates!

👩‍🔬Sessions chaired by Prostate Cancer UK Career Acceleration Fellows.
🎤30 brilliant researchers sharing Research Snapshots.
🚀All #ProstateCancer researchers welcome.
🗓️Check the webpage for agenda & registration.
👇
prostatecanceruk.org/research/for...

Person sitting on a couch working on a Lenovo laptop.

🎦 Watch on-demand: Dr Bunmi Olajide & @NASGP.bsky.social present a focused session on early detection of prostate cancer in the UK.

Tailored for primary care, the webinar covers:
🔷Risk assessment
🔷PSA testing
🔷Tackling health inequalities

➡️View here bit.ly/46a5WyZ

Professor Gerhardt Attard holding a pipette.

The September edition of Research News is here! Find out more about:

💊 Exciting Research Findings.
🤝 Researcher Mentoring Scheme.
🏆 A Researcher Achievement.
💻 Upcoming New Seminar Series.
💰 Funding Opportunities.

📖 Read it here: prostatecanceruk.org/research/for...

👇A great opportunity to work on exciting new #ProstateCancer research in the brilliant @bevanlab.bsky.social

Person using earphones and looking thoughtfully at a computer screen in an office setting.

🔊 Don’t miss Dr Bunmi Olajide on @nasgp.bsky.social! Key prostate cancer updates for primary care in one podcast.

➡️ Listen now bit.ly/3VGEBOC

Scientific Paper Published in The Journal of the American Medical Association, titled: Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial. Written by Ng et al.

Could faster MRI scans allow more men to receive timely #ProstateCancer diagnoses?

Research published in @jama.com led by @veerukasi.bsky.social, Dr Alex Ng & Dr Aqua Asif at @ucl.ac.uk compares the efficacy of shortened versus standard-length scans.

Grab a ☕ & read: doi.org/10.1001/jama...

Early detection of prostate cancer in primary care NASGP · Episode

🎧 Tune in to our new @nasgp.bsky.social podcast with Dr Bunmi!

Everything primary care needs to know on prostate cancer:
🔵 Epidemiology & risk factors
🔵 Health inequalities
🔵 NICE NG12 & PSA thresholds
🔵 mpMRI, DRE & the TRANSFORM trial

➡️ Listen on Spotify: bit.ly/4maj9ME

Person wearing earphones sits at a desk with books and a computer, appearing thoughtful.

How confident are you in spotting & managing prostate cancer early?

In our latest podcast with @nasgp.bsky.social & Dr Bunmi, we cover:

🔷UK epidemiology & risk factors
🔷PSA thresholds, mpMRI & DRE
🔷Health inequalities & TRANSFORM

➡️ A must-hear for primary care: bit.ly/3VGEBOC

Can microbial communities be linked to specific cancer types, including #ProstateCancer?

A team @UeaMedical.bsky.social including Career Acceleration Fellow @AbrahamGihawi.bsky.social use @GenomicsEngland.bsky.social data to examine these links.

Grab a ☕ and read: buff.ly/HRJA9oc

Prostate Cancer UK man icon holding a pipette

[8/8] 📖 If you would like to learn more about why this research is so important for men with advanced #ProstateCancer, you can read more about the project in our latest News & Views article: prostatecanceruk.org/about-us/new...

A man with a happy expression, smiling and enjoying time with his friends.

[7/8] Impact:

🖊️ Tools that analyse tumour transcriptomes can pinpoint which men with advanced #ProstateCancer are likely to benefit from chemotherapy.

💙 This helps men avoid unnecessary chemotherapy and its associated side effects, ultimately enhancing their quality of life.

Graph showing that men with tumours exhibiting PTEN loss are more likely to benefit from combined chemotherapy and hormone therapy treatment.

[6/8] Next, the team identified:

✅ In men with advanced #ProstateCancer, PTEN inactivity is associated with shorter survival on hormone therapy but predicts a greater survival benefit from docetaxel compared to PTEN-active tumours.

Graph showing that men with high Decipher scores benefit from combining docetaxel chemotherapy with standard hormone therapy, whereas those with low scores do not.

[5/8] First, the study revealed:

✅ The Decipher signature is prognostic and helps identify men with advanced #ProstateCancer who are most likely to benefit from docetaxel.

Schematic illustrating the workflow for processing biopsies from men, including central H&E review, tumour macrodissection, microarray hybridization, and quality control analysis.

[4/8] 🧬 The team analysed transcriptomes from 1,523 biopsies of men previously enrolled in the STAMPEDE trial using the Decipher signature and a signature that assesses PTEN activity, to evaluate their effectiveness in guiding treatment stratification.

Prof Gerhardt Attard

[3/8] 💊 Yet, while docetaxel extends survival for some men, responses vary, and clinicians have limited tools to predict who will benefit.

💡The team explored whether transcriptome analysis tools could identify men likely to benefit from docetaxel, with a particular focus on the Decipher signature.

STAMPEDE clinical trial logo

[2/8] The STAMPEDE trial, led by @prof-nick-james.bsky.social and funded by @cancerresearchuk.org, showed that combining docetaxel chemotherapy with standard hormone therapy significantly improves outcomes for men with advanced #ProstateCancer.

Prostate Cancer UK Professionals (@prostateukprofs.bsky.social) Could transcriptome signatures identify men with advanced #ProstateCancer most likely to benefit from chemotherapy? A brilliant team led by Prof Gerhardt Attard @ucl.ac.uk share exciting new findings…

[1/8] 🔎 Let’s take a closer look at the exciting findings from the Prostate Cancer UK funded study led by Prof Gerhardt Attard and team @ucl.ac.uk recently published in @cp-cell.bsky.social 🧵.

Scientific Paper Published in Cell, titled: Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers. Written by Grist et al.

Could transcriptome signatures identify men with advanced #ProstateCancer most likely to benefit from chemotherapy?

A brilliant team led by Prof Gerhardt Attard @ucl.ac.uk share exciting new findings in @cp-cell.bsky.social.

Grab a ☕ and read: doi.org/10.1016/j.ce...

Four people in a discussion inside an office setting. Two individuals are seated and listening intently to another who is speaking, while a fourth observes. A poster reading "NHS" is visible in the background, indicating a healthcare context.

Dr Abel Tesfai shares key insights from experts from our first ever Health Inequalities Conference and outlines steps being taken to strengthen the real-world evidence landscape for Black men.

Read more about it here ⤵️ bit.ly/3ZNWw8K

#HealthEquity #ProstateCancer

Could #AI support clinicians to accurately contour organs-at-risk before #ProstateCancer radiotherapy?

A team of researchers @qubelfastofficial.bsky.social led by Dr Conor McGarry compare AI- and clinician-generated rectum contours.

Grab a ☕ and read: doi.org/10.1088/2057...

Health Improvement Map This map highlights Prostate Cancer UK's efforts to improve early detection and patient care for men across the NHS, government and community sectors in the UK.

Health engagement map!

Thanks to your commitment to health education & training, support is reaching men across the UK.💙

🗺️ Explore our map to see what we’ve achieved and how together we’re striving for a world where no man dies from prostate cancer ⬇️